Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Non-Current Deffered Revenue (2016 - 2023)

Theravance Biopharma (TBPH) has disclosed Non-Current Deffered Revenue for 11 consecutive years, with $175000.0 as the latest value for Q3 2023.

  • Quarterly Non-Current Deffered Revenue fell 12.06% to $175000.0 in Q3 2023 from the year-ago period, while the trailing twelve-month figure was $175000.0 through Sep 2023, down 12.06% year-over-year, with the annual reading at $192000.0 for FY2022, 38.06% down from the prior year.
  • Non-Current Deffered Revenue for Q3 2023 was $175000.0 at Theravance Biopharma, down from $181000.0 in the prior quarter.
  • The five-year high for Non-Current Deffered Revenue was $21.7 million in Q1 2019, with the low at $175000.0 in Q3 2023.
  • Average Non-Current Deffered Revenue over 5 years is $3.7 million, with a median of $329000.0 recorded in 2021.
  • The sharpest move saw Non-Current Deffered Revenue soared 101.32% in 2019, then crashed 96.02% in 2021.
  • Over 5 years, Non-Current Deffered Revenue stood at $6.8 million in 2019, then crashed by 94.85% to $348000.0 in 2020, then fell by 10.92% to $310000.0 in 2021, then plummeted by 38.06% to $192000.0 in 2022, then decreased by 8.85% to $175000.0 in 2023.
  • According to Business Quant data, Non-Current Deffered Revenue over the past three periods came in at $175000.0, $181000.0, and $187000.0 for Q3 2023, Q2 2023, and Q1 2023 respectively.